Video

What Treatment Options Are Being Studied for Patients with Type 2 Diabetes?

Conference|APhA Annual Meeting and Exposition - American Pharmacists Association Annual Meeting and Exposition

There are several new options coming down the pipeline for patients with type 2 diabetes.

In this clip, Dhiren Patel, PharmD, CDE, BC-ADM FCCP, who is a professor of pharmacy practice at Massachusetts College of Pharmacy and Health Sciences School of Pharmacy, discusses with Pharmacy Times the treatment pipeline and what's next for treating patients with diabetes.

Dr. Patel discussed managing diabetes with insulin/GLP-1 receptor agonist combinations during a special session held in conjunction with APhA2017.

Related Videos
Related Content
Concept of FDA Food and Drug Administration - Image credit: wladimir1804 | stock.adobe.com
December 22nd 2024

Selective Antisense Oligonucleotide-based JAK2 Inhibitor Receives FDA Orphan Drug Designation for Polycythemia Vera

Kennedy Ferruggia, Assistant Editor
Public Health Matters: Pharmacists as Frontline Health Providers: Collaborating for Better Patient Outcomes
November 21st 2024

Public Health Matters: Pharmacists as Frontline Health Providers: Collaborating for Better Patient Outcomes

Christina M. Madison, PharmD, FCCP, AAHIVP
FDA website homepage -- Image credit: Postmodern Studio | stock.adobe.com
December 21st 2024

FDA Approves Alyftrek, Once-Daily CFTR Modulator for Cystic Fibrosis

Gillian McGovern, Assistant Editor
Public Health Matters podcast logo
September 19th 2024

Public Health Matters: The Difference Between Misinformation and Disinformation, and How Information Can Inform Evidence-Based Decisions

Sleepless, man suffering from insomnia, sleep apnea or stress. Tired and exhausted guy. Headache or migraine. Awake in the night.
December 20th 2024

FDA Approves Tirzepatide as First Treatment for Moderate-to-Severe Obstructive Sleep Apnea in Adults With Obesity

Luke Halpern, Assistant Editor
FDA Approval, Weight Loss, Pediatrics | Image Credit: Aquir | stock.adobe.com
December 20th 2024

FDA Approves Expanded Indication for Setmelanotide to Include Patients 2 and Older

Ashley Gallagher, Associate Editor